APP and Alzheimer disease: Based on these evidences, we tested the same regime of 1-month chronic fingolimod treatment (compare with Methods) that we reported previously to rescue AD deficits in APP/PS1 mice (compare [10]) for its potential to rescue 6× 1:4 t-LTP deficits in CA1 neurons near to Aβ plaques.